Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T04:41:15.123Z Has data issue: false hasContentIssue false
  • English
  • Français

Cytokine levels in patients with Epstein–Barr virus associated laryngeal carcinoma

Published online by Cambridge University Press:  08 June 2010

S Rota ,
I Fidan ,
T Muderris ,
E Yesilyurt  and
Z Lale
S Rota
Affiliation:
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey
I Fidan*
Affiliation:
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey
T Muderris
Affiliation:
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey
E Yesilyurt
Affiliation:
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey
Z Lale
Affiliation:
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey
*
Address for correspondence: Dr Isil Fidan, Department of Medical Microbiology, Faculty of Medicine, Gazi University, Dekanlik Binasi 2 Kat, Besevler, Ankara 06500, Turkey. Fax: +90 312 4358632 E-mail: isilfidan@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Some researchers have suggested that Epstein–Barr virus may play a role in the pathogenesis of laryngeal malignancies. In order to clarify the role of cytokines in this disease context, the current study aimed to determine the serum levels of cytokines in Epstein–Barr virus DNA positive patients with laryngeal carcinoma.

Subjects:

The study included 10 patients with diagnosed laryngeal carcinoma and Epstein–Barr virus DNA positive tumour tissue samples. The control group comprised 10 Epstein–Barr virus DNA negative patients diagnosed with laryngeal carcinoma, 10 patients with acute Epstein–Barr virus infection and 10 healthy individuals.

Method:

Serum cytokine levels were determined by enzyme-linked immunosorbent assay.

Results:

The Epstein–Barr virus DNA positive and negative laryngeal carcinoma patients showed no differences regarding serum levels of the following cytokines: interleukins 1β, 2, 6 and 12, tumour necrosis factor α, and interferon γ. However, serum levels of interleukin 10 and transforming growth factor β1 were significantly higher in Epstein–Barr virus DNA positive laryngeal carcinoma patients compared with Epstein–Barr virus DNA negative laryngeal carcinoma patients (p < 0.05).

Conclusion:

Our results suggest that the cytokines interleukin 10 and transforming growth factor β1 may act as growth factors in Epstein–Barr virus related laryngeal carcinoma. These cytokines may thus represent potential targets for molecular therapeutic treatment for laryngeal carcinoma; they may also be useful as indicators of disease prognosis.

Keywords

Larynx NeoplasmsCytokinesPolymerase Chain ReactionPrognosis
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 124 , Issue 9 , September 2010 , pp. 990 - 994
Copyright
Copyright © JLO (1984) Limited 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1de Oliveira, DE, Bacchi, MM, Macarenco, RS, Tagliarini, JV, Cordeiro, RC, Bacchi, CE. Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. Am J Clin Pathol 2006;126:284–93CrossRefGoogle ScholarPubMed
2Baumann, JL, Cohen, S, Evjen, AN, Law, JH, Vadivelu, S, Attia, A et al. Human papillomavirus in early laryngeal carcinoma. Laryngoscope 2009;119:1531–7CrossRefGoogle ScholarPubMed
3Korcum, AF, Özyar, E, Ayhan, A. Epstein-Barr virus genes and nasopharyngeal cancer. Turk J Cancer 2006;36:97–107Google Scholar
4Nilsson, C, Larsson Sigfrinius, AK, Montgomery, SM, Sverremark-Ekström, E, Linde, A, Lilja, G et al. Epstein-Barr virus and cytomegalovirus are differentially associated with numbers of cytokine-producing cells and early atopy. Clin Exp Allergy 2009;39:509–17CrossRefGoogle ScholarPubMed
5Thompson, MP, Kurzrock, R. Epstein-Barr virus and cancer. Clin Can Res 2004;10: 803–21CrossRefGoogle ScholarPubMed
6Baumforth, KR, Young, LS, Flavell, KJ, Constandinou, C, Murray, PG. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307–22CrossRefGoogle ScholarPubMed
7Li, J, Zeng, X, Mo, H, Rolén, U, Gao, Y, Zhang, X et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007;7;2:e1122CrossRefGoogle ScholarPubMed
8Hornerf, MW, Wagner, HJ, Kruse, A, Kirchner, H. Cytokine production in a whole blood assay after Epstein-Barr virus infection in vivo. Clin Diagn Lab Immunol 1995;2:209–13CrossRefGoogle Scholar
9Mansoori, SD, Shahgasempour, S. Proliferation of cytotoxic and activated T cells during acute Epstein-Barr virus induced infectious mononucleosis. Acta Med Iranica 2002;40:6–10Google Scholar
10Opal, SM, DePalo, VA. Anti-inflammatory cytokines. Chest 2000;117:1162–72CrossRefGoogle ScholarPubMed
11Eckmann, L, Kagnolf, MF. Cytokines in host defense against salmonella. Microb Infect 2001;3:1191–200CrossRefGoogle ScholarPubMed
12Ohga, S, Nomura, A, Takada, H, Hara, T. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol 2002;44:203–15CrossRefGoogle ScholarPubMed
13Chua, HH, Yeh, TH, Wang, YP, Sheen, TS, Shew, JY, Huang, YT et al. Regulation of IAPs gene family by interleukin-1 alpha and Epstein-Barr virus in nasopharyngeal carcinoma. Head Neck 2008;30:1575–85CrossRefGoogle ScholarPubMed
14Khan, G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006;34:399–406CrossRefGoogle ScholarPubMed
15Tan, EL, Selvaratnam, G, Kananathan, R, Sam, CK. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-β1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 2006;6:227–34CrossRefGoogle ScholarPubMed
16Kapral, M, Strzalka, B, Kowalczyk, M, Jurzak, M, Mazurek, U, Gierek, T et al. Transforming growth factor β isoforms (TGF-β1, TGF-β2, TGF-β3) messenger RNA expression in laryngeal cancer. Am J Otolaryngol 2008;29:233–7CrossRefGoogle ScholarPubMed
17Xu, J, Ahmad, A, Jones, JF, Dolcetti, R, Vaccher, E, Prasad, U et al. Elevated serum transforming growth factor β 1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J Virol 2000;74:2443–6CrossRefGoogle ScholarPubMed
18Ho, JWY, Liang, RHS, Srivastava, G. Differential cytokine expression in EBV positive peripheral T cell lymphomas. J Clin Pathol Mol Pathol 1999;52:269–74CrossRefGoogle ScholarPubMed
19Jebreel, A, Mistry, D, Loke, D, Dunn, G, Hough, V, Oliver, K et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246–52CrossRefGoogle Scholar
20Budiani, DR, Hutahaean, S, Hayrana, SM, Soesatyo, MHNE, Sosroseno, W. Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J Microbiol Immunol Infect 2002;35:265–8Google ScholarPubMed
21Ogino, T, Moriai, S, Ishida, Y, Ishii, H, Katayama, A, Miyokawa, N et al. Associated of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007;120:2401–10CrossRefGoogle ScholarPubMed
22Fukuda, M, Ikuta, K, Yanagihara, K, Tajima, M, Kuratsune, H, Kurata, T et al. Effect of transforming growth factor-β1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines. Virology 2001;288:109–18CrossRefGoogle ScholarPubMed
23Chen, HW, Yang, SF, Chang, YC, Wang, TY, Chen, YJ, Hwang, JJ. Epstein-Barr virus infection and plasma transforming growth factor-β1 levels in head and neck cancers. Acta Otolaryngol 2008;128:1145–51CrossRefGoogle ScholarPubMed